1Hanifi-Moghaddam P, Gielen SC, Kloosterboer H J, et al. Molecular portrait of the progestagenic and estrogenic actions of tibolone: be havior of cellular networks in response to tibolone. J Clin Endocrinol Metab, 2005, 90(1): 973-983.
2Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol,i999,106 [Suppl 19]:1-21.
3Sperfff L, Clarkson T. Is Tibilone a vilable arternative to HT ? Cont Obstet Gynecol, 2003, 48( 1):54-68.
4Landgren MB, Coelingh H J, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG, 2002,109(10):1109-1114.
5Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized,double-blind, placebo-control, dose-finding studies. J Clin Endocrinol Metab, 2001,86(10):4717-4726.
6Huber J, Palacios S, Berglund L, et al. Effects of tibilone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. B JOG,2002,109(8):886-893.
7Morris EP, Wilson PO, Robinson J, et al. Long term effects of tibilone on the genital tract in postmenopausal women. Br J Obstet Gynaecol,1999, 106(9): 954-959.
8Fenkci V, Yilmazer M, Fenkci S. Effects of short-time (3 months) tibilone on bone turnover in postmenopausal women. Arch Gynecol Obstet, 2003, 268(8): 85-87.
9Ederveen AG, Klooster HJ. Tibolone exerts an estrogenic effect on bone leading to preventiom of bone loss and reduction in bone resorption in ovariectomized rats. Osteoporosis Int, 1998,8[Suppl]:293.
10Koh KK, Ahn JY, Kyu D, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomoized, double-blind, placebocontrolled, crossover study. Arterioscler Thromb Vasc Biol, 2003, 23(8): 1889-1894.
